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Summary
Purpose:  To  make  a  ﬁeld  comparison  of  the  effectiveness,  ease  of  use,  and  cost  of  a
chlorhexidine  antiseptic  solution  (CBA)  and  an  alcohol-based  povidone-iodine  solu-
tion  (PVP-IA)  for  the  prevention  of  central  venous  catheter  (CVC)-related  infections
in  an  intensive  care  unit,  with  the  aim  of  identifying  the  superior  antisepsis  agent.
Materials  and  methods:  We  measured  the  CVC  colonization  and  infection  incidence
for  PVP-IA  (Betadine  alcoolique®)  and  for  CBA  (Biseptine®) during  two  successive
1-year  periods  of  routine  surveillance  (REA  RAISIN  network).  A  questionnaire  on
the  ease  of  CBA  use  was  administered.  Consumption  data  were  obtained  from  the
hospital  pharmacy.
Results:  The  study  included  806  CVC  (CBA  period:  371).  Upon  switching  from  PVP-IA
to  CBA,  we  recorded  a  signiﬁcant  reduction  in  colonization  incidence/100  catheter
days  (1.12  vs.  1.55,  p  =  0.041),  nonsigniﬁcant  differences  concerning  CVC-related
infection  incidence/100  catheter  days  (0.28  vs.  0.26,  p  =  0.426),  and  a nonsigniﬁcant
reduction  in  CVC-related  bacteremia/100  catheter  days  (0.14  vs.  0.30,  p  =  0.052).
PVP-IA  users  were  at  signiﬁcantly  higher  risk  of  CVC  colonization  or  infection  based
on  a  multivariate  Cox  model  analysis  (relative  risk  [95%  CI]:  1.48  [1.01—2.15],
p  =  0.043).  The  main  drawbacks  of  CBA  use  were  its  low  cleansing  activity  and  its
colorless  solution.  No  cost  advantage  was  found.
Conclusions:  Our  ﬁeld  study  revealed  no  major  clinical  advantage  of  CBA  use  in  CVC
infection  and  no  cost  advantage  in  addition  to  limited  ease  of  use.
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Introduction
The  use  of  central  venous  catheters  (CVC)  in  inten-
sive care  units  is  widespread  but  is  associated
with potentially  serious  infections.  Prevention  of
these infections  is  addressed  in  guidelines  that  are
regularly  updated  as  new  studies  are  published
[1,2].
For catheter  insertion  and  care,  different
antiseptic formulations  that  involve  the  use  of
povidone-iodine  or  chlorhexidine  are  used  most
frequently.  The  povidone-iodine  solution,  widely
used in  France,  was  available  ﬁrst  in  aqueous
solution and  more  recently  as  an  ethanol-based
solution (Betadine  alcoolique®).  Parienti  et  al.
used the  PVP-IA  and  found  it  to  be  more  effec-
tive than  the  aqueous  solution  [3].  Currently,
PVP-IA is  considered  to  be  the  preferred  prod-
uct for  CVC  care.  Chlorhexidine  is  more  common
than povidone-iodine  in  other  countries,  is  avail-
able at  different  concentrations  (0.5—4%)  and
can be  used  alone  or  in  association  with  other
products (alcohol  or  others).  Historically,  several
studies  have  shown  that  for  catheter  insertion
and care,  chlorhexidine  seems  to  have  a  better
antiseptic effect  than  povidone-iodine.  In  a meta-
analysis, Chaiyakunapruk  et  al.  [4]  concluded  than
chlorhexidine  use  is  associated  with  a  reduction
of catheter-related  bloodstream  infection  and  a
consistent reduction  of  costs  [5],  but  all  8 studies
included  in  the  meta-analysis  compared  an  aque-
ous solution  of  povidone-iodine  to  alcohol  based
or aqueous  chlorhexidine  solutions.  The  same  ref-
erence solution  was  used  by  Humar  et  al.  in  a
study on  CVC-related  infections  [6]  and  by  Lang-
gartner  et  al.  in  a  study  on  CVC  colonization
[7]. A  large  number  of  international  studies  have
explored  different  chlorhexidine  antisepsis  (with
or without  alcohol  or  at  different  concentrations),
but the  reference  solution  was  an  aqueous  solu-
tion of  povidone-iodine  in  each  case  [8—10].  More
recently,  Mimoz  et  al.  compared  a  recently  devel-
oped chlorhexidine-based  antiseptic  (CBA)  solution
(0.25%  chlorhexidine  gluconate,  0.025%  benzalko-
nium  chloride  and  4%  benzyl  alcohol,  Biseptine®)
to PVP-IA  and  found  CBA  to  be  more  effective
[11].
Our unit  has  used  PVP-IA  since  2006.  However,
because many  intensive  care  units  in  France  chose
chlorhexidine,  we  decided  to  conduct  a  ﬁeld  test  on
PVP-IA and  this  new  CBA  solution  that  was  tested
by Mimoz  et  al.  to  determine  whether  it  would
be worthwhile,  in  terms  of  effectiveness,  ease  of
use, and  cost,  to  switch  to  CBA  for  CVC-related
care.
(
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aterials and methods
esign and setting
his  prospective  longitudinal  ﬁeld  study  was  con-
ucted within  our  routine  surveillance  program
or hospital-acquired  infections  (the  REA  RAISIN
urveillance  network)  [12].  This  network  is  the
rench organization  for  the  nosocomial  infection
urveillance network  of  the  European  Centre  for
isease Prevention  and  Control.  It  includes  each
atient hospitalized  in  an  intensive  care  unit;
or each  patient,  the  following  data  are  col-
ected, using  standardized  deﬁnitions:  infectious
isk, exposure  and  acquired  infections.
atients and intervention
ll  patients  who  spent  at  least  2  days  in  our  med-
cal ICU  between  January  2007  and  June  2009
nd in  whom  at  least  one  CVC  was  inserted  were
ncluded in  the  study.  The  CVCs  were  nontun-
eled; single-,  double-  or  triple-lumen;  without
 cuff;  and  without  antimicrobial  impregnation.
e used  PVP-IA  until  June  1,  2008,  and  there-
fter recommended  the  use  of  CBA  (Biseptine®).
iseptine® is  an  aqueous  solution  containing  0.25%
HG, 0.025%  benzalkonium  chloride,  and  4%  benzyl
lcohol (Bayer  Santé  Familiale,  Gaillard,  France).
he protocols  for  CVC  insertion  and  care  were  as
ollows:  (i)  cleaning  with  a  PVP-I  scrub  (Betadine
crub®, Meda  Pharma,  Paris,  France),  rinsing  with
terile water,  drying  with  a swab,  and  the  applica-
ion of  PVP-IA  (Betadine  alcoolique®,  Meda  Pharma,
aris, France)  and  (ii)  cleaning  with  CBA,  drying
ith a swab,  and  a second  CBA  application.  All  staff
eceived instruction  in  the  CBA  protocol.  All  CVCs
emoved  in  the  unit  were  sampled  and  tested  by  the
ame method.  For  patients  discharged  from  the  hos-
ital with  a CVC,  the  duration  of  CVC  use  included
nly use  in  the  ICU.  Povidone  was  used  in  the  units
or many  purposes,  such  as  urinary  catheters  and
racheal suction  in  cases  that  required  intubation.
t could  not  be  excluded  from  the  unit  during  the
est period,  but  it  was  never  used  for  CVC,  as  con-
rmed by  two  investigators.
ata collection
CU  physicians  collected  data  on  patient  age,
ender, Simpliﬁed  Acute  Physiology  Score  (SAPS
I), immunodeﬁciencies,  and  invasive  procedures
including their  duration).  They  recorded  the  date
f CVC  insertion  and  removal  as  well  as  the  site  of
VC insertion.
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CVC  tip  colonization  was  assessed  using  a
emiquantitative  culture  method.  A  CVC-related
nfection was  deﬁned  as  the  (1)  presence  of  local
igns of  infection  (pus,  inﬂammation  or  pain)  or
f general  signs  of  infection  together  with  (2)  evi-
ence for  CVC  colonization  or  a  ≥5-fold  higher
acterial count  for  the  CVC  tip  than  for  a  paired
uantitative peripheral  blood  culture,  with  (3)
pontaneous  resolution  within  48  h  of  CVC  removal.
VC-related  bacteremia  was  deﬁned  as  bacteremia
nset 48  h  before  or  after  CVC  removal,  as  evi-
enced by  at  least  one  positive  blood  culture  from
 peripheral  blood  sample  containing  a microorgan-
sm that  was  also  found  (1)  in  a  paired  quantitative
lood culture,  (2)  in  a  positive  culture  from  the
nsertion  site  or  (3)  in  CVC  tip  colonization.
utcome measures
roduct  efﬁcacy  was  evaluated  by  determining
VC colonization,  CVC-related  infection  and  CVC-
elated bacteremia  rates.  A  univariate  analysis  was
erformed  to  compare  both  periods.
The comparison  between  PVP-IA  and  CBA  could
e biased  by  confounding  factors,  such  as  disease
everity  (SAPS  II),  duration  of  CVC  use,  exposure  to
ther factors,  and  patients  with  immunodeﬁciency.
n an  effort  to  test  the  speciﬁc  effect  of  antisep-
is, multivariate  analysis  was  performed.  To  obtain
etter statistical  power,  the  survival  without  any
vidence  of  CVC  infections  (colonization,  infection
r bacteremia)  was  preferred  to  a  separate  analy-
is.
The ease  of  CBA  use  was  evaluated  by  a  ques-
ionnaire administered  in  May  2009  to  all  ICU  staff
embers  (physicians  and  nurses).  Items  covered
ottle quality  (size,  ease  of  pouring  and  risk  of
pilling),  cleansing  capacity,  presentation  (color-
ess solution),  protocol  simplicity,  tolerance,  and
aceration.  Each  item  was  evaluated  on  a  4-point
ikert  scale  [13]  (1  point  if  the  response  was
‘completely disagree’’,  2  points  if  it  was  ‘‘rather
isagree’’,  3  points  if  it  was  ‘‘rather  agree’’  and  4
oints if  it  was  ‘‘completely  agree’’).
The costs  incurred  by  CBA  use  compared  with
VP-IA use  were  evaluated  based  on  consumption
gures provided  by  the  hospital’s  pharmacy  (last  7
onths of  2007  for  PVP-IA  and  last  7 months  of  2008
or CBA).  The  ICU  bed  occupancy  was  similar  for  the
wo periods.
tatisticsata  were  entered  and  analyzed  by  the  Hygiene
nd Epidemiology  Unit  using  Epi  Info  2002  and
PSS V17  software.  Standard  statistical  tests  were
f
d
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sed:  Fisher’s  exact  test  and  Pearson’s  chi-squared
est  for  more  than  2 situations  were  used  for  the
omparison  of  percentages;  nonparametric  tests
Mann—Whitney  U-test)  were  used  for  numerical
ata, many  being  nonnormally  distributed,  and  the
 test  was  used  for  incidence  rate  comparisons.
For multivariate  analysis,  a  Cox  model  was  used
or the  comparison  of  survival  of CVC  without  an
nfection-related  problem.  Each  factor  related  to
nfectious  risk  in  univariate  analysis  and  interac-
ions  were  included  in  the  model.
esults
atient and CVC characteristics
he  study  included  640  patients,  292  (45.6%)  of
hom were  evaluated  during  the  period  of CBA  use.
 total  of  806  CVCs  were  inserted  (1.3/patient)  for
 total  of  8567  days.  Patient  and  CVC  characteristics
re given  in  Table  1.  During  the  period  of  CBA  use,
he included  patients  were  signiﬁcantly  younger
p =  0.047)  and  heavier  (p  =  0.005);  the  rate  of  CVC
nsertion  by  the  femoral  route  was  signiﬁcantly
igher (p  <  0.001),  and  the  mean  duration  of  CVC
se in  the  ICU  was  signiﬁcantly  longer  (p  =  0.007).
olonization and infection rates
olonization  and  infection  rates  are  compared  in
able 2  for  the  two  periods.  During  CBA  use,  the
ncidence  of  CVC  colonization  per  1000  catheter
ays, but  not  the  overall  incidence  of  CVC  colo-
ization, was  signiﬁcantly  lower  than  during  PVP-IA
se (p  =  0.041).  Both  the  overall  incidence  of  infec-
ion and  the  incidence  per  1000  catheter  days
ere higher  but  not  signiﬁcantly  so.  The  overall
ncidence of  CVC-related  bacteremia  and  the  inci-
ence per  1000  catheter  days  were  lower.  The
atter  reached  borderline  signiﬁcance  (1.4  vs.  3.0,
 =  0.052).  The  incidence  of  CVC  colonization  per
000 catheter  days  was  signiﬁcantly  higher  for  the
emoral compared  with  the  subclavian  route  (1.9
s. 0.8,  p <  0.001),  but  no  signiﬁcant  difference  was
ound between  the  two  routes  for  the  incidence  per
000 catheter  days  of  CVC-related  infection  or  bac-
eremia. Staphylococcus  epidermidis  was  the  main
icroorganism  that  was  identiﬁed  during  these  two
eriods.
A Cox  multivariate  analysis  considered  the  dif-erences  in  populations,  CVCs,  practices,  and
uration  of  CVC  use.  It  also  compared  coloniza-
ion and  infection-free  survival  as  functions  of
actors that  could  possibly  be  associated  with  the
38  R.  Girard  et  al.
Table  1  Patient  and  CVC  characteristics.
Total
population
PVP-IA
period
CBA period  p  between
the  2  periods
Patients
Total  number  640  348  (54.4)  292  (45.6)  —
Male  gender 383  (59.8)  209  (60.1)  174  (59.6)  0.904*
Mean  age  (yrs) 63.0  ±  15.3 64.1  ±  14.4  61.6  ±  14.9  0.047**
SAPS  II 53.0  ±  41.2 52.6  ±  53.8 53.5  ±  16.8 0.005**
Antibiotics  at  admission 511  (79.8) 277  (79.6) 234  (80.1) 0.865*
Immunodeﬁciency 138  (21.6) 80  (23.0) 58  (19.9) 0.338*
Indwelling  catheter  611  (5.5)  330  (94.8)  281  (96.2)  0.395*
Hospital-acquired  urinary  infection  62  (9.7)  34  (9.8)  28  (9.6)  0.939*
Intubation  496  (77.5)  266  (76.4)  230  (78.8)  0.482*
Hospital-acquired  lung  disease  84  (13.1)  40  (11.5)  44  (15.1)  0.182*
Bacteremia  29  (4.5)  14  (4.0)  15  (5.1)  0.500*
Mean  stay  in  hospital  (days)  13.2  ±  18.1  12.5  ±  19.5  14.0  ±  16.4  0.070**
Mean  duration  of  intubation  (days)  10.7  ±  17.3  9.8  ±  18.5  11.7  ±  15.7  0.025**
Mean  duration  of  bladder  catheterization  (days)  13.5  ±  15.8  12.7  ±  16.4  14.6  ±  15.1  0.038**
Mean  duration  of  ﬁrst  CVC  use  (days)  10.3  ±  8.3  9.8  ±  8.1  10.7  ±  8.5  0.278**
CVCs
Total  number  of  CVCs 806 435  (100)  371  (100)  —
Insertion  site
Subclavian 300  (37.8) 178  (41.0) 122  (34.0)  <0.001***
Jugular 128  (16.1) 88  (20.3)  40  (11.1)
Femoral 363  (45.8) 196  (38.5) 167  (54.6)
CVC  not  removed  before  discharge  from  ICU 253  (31.5) 136  (31.3) 117  (31.88) 0.872*
Duration  of  CVC  use  in  ICU  (days) 10.6  ±  8.6 9.8  ±  8.0 11.6  ±  9.1 0.007**
Results given as n (%) or mean ± SD.
* Fischer exact test.
C
h
r
o** Non-parametric Mann and Whitney test.
*** Pearson chi square test.
risk  of  CVC  colonization  or  CVC-related  infection,
i.e., patient  age  and  gender,  SAPS  II,  immun-
odeﬁciencies,  antibiotic  treatment  at  admission,
intubations (including  duration),  bladder  catheteri-
zation  (including  duration),  other  hospital-acquired
infections, and  the  CVC  insertion  site.  Univariate
and multivariate  analysis  are  presented  in  Table  3.
t
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Table  2  CVC  colonization  and  CVC-related  infections.
PVP-IA  pe
Number  of  CVCs  435  (100)
Number  of  days  4263  
CVC  colonization
Number  (attacks  rate  %)  66  (15.2)
Incidence  (/1000  catheter  days) 15.5  
CVC-related  local  or  general  infections
Number  (attacks  rate  %) 11  (2.5)
Incidence  (/1000  catheter  days) 2.6
CVC-related  bacteremia
Number  (attacks  rate  %)  13  (3.0)  
Incidence  (/1000  catheter  days)  3.0  
Results given as n (%).
* Fischer exact test, or Z test for incidence rates.ompared  with  CBA  use,  PVP-IA  is associated  with  a
igher risk  of  CVC  colonization  or  infection  (relative
isk (RR)  [95%  CI]:  1.48  [1.01—2.15],  p  =  0.04).  The
nly other  signiﬁcant  factor  with  regard  to  coloniza-
ion or  infection  was  the  duration  of  CVC  use  (RR:
.98 [0.96—0.99],  p <  0.001).  A  plot  of  colonization
nd infection-free  survival  revealed  that  the  curves
riod  CBA  period  p*
 371  (100)  —
4304  —
 48  (12.9)  0.365
11.2  0.041
12  (3.2) 0.548
2.8  0.426
6  (1.6)  0.201
1.4  0.052
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Table  3  Analysis  of  CVC  infection  or  colonization  risk  factors.
CVC
infection  or
colonization
No infection,
no
colonization
p
(1)  Univariate  analysis
Total  number  of  CVC 114  (14.4) 692  (85.6) —
Male  gender 72  (63.2) 423  (61.1) 0.756*
Mean  age  (yrs) 65.2  ±  14.7 63.3  ±  14.7 0.202**
SAPS  II 54.2 ±  17.2 54.6  ±  53.6 0.166**
Antibiotics  at  admission  100  (87.7)  553  (79.9)  0.053*
Immunodeﬁciency  19  (16.7)  157  (22.7)  0.178*
Indwelling  catheter  113  (99.1)  664  (96.0)  0.106*
Hospital-acquired  urinary  infection  20  (17.5)  76  (11.0)  0.060*
Intubation 104  (91.2)  543  (78.5)  0.001*
Hospital-acquired  lung  disease  29  (25.4)  121  (17.5)  0.051*
Bacteremia  19  (16.7)  35  (5.1)  <0.001*
Mean  stay  in  hospital  (days)  25.2  ±  26.4  15.6  ±  22.2  <0.001**
Mean  duration  of  intubation  (days)  21.8  ±  24.7  12.9  ±  21.7  <0.001**
Mean  duration  of  bladder  catheterization  (days)  24.7  ±  24.5  16.0  ±  20.7  <0.001**
Mean  duration  of  CVC  use  (days) 13.6  ±  8.7  10.1  ±  8.4  <0.001**
CBA  period 48  (42.1) 323  (46.7)  0.417*
Insertion  site
Subclavian 25  (21.9) 275  (40.5) <0.001***
Jugular 15  (13.2) 113  (16.6)
Femoral 74  (64.9) 289  (42.6)
Signiﬁcant  factors  Relative  risk  95%  CI  of  RR  p
(2)  Cox  model  analysis  on  survival  without  colonization  or  infection
PVP-IA  period/CBA  period  mean  1.475  1.012—2.150  0.043
Duration  of  bladder  catheterization  (days)  0.977  0.964—0.990  <0.001
Results given as n (%) or mean ± SD.
Non signiﬁcant variables in the model: patient age, gender, SAPS II, immunodeﬁciency, antibiotic treatment at admission, duration
of intubations, other hospital-acquired infections, and CVC insertion site.
* Fischer exact test.
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p** Non-parametric Mann and Whitney test.
*** Pearson chi squared test.
or  each  study-period  did  not  coincide.  The  ﬁrst
pisode  of  infection  or  colonization  occurred  later
uring the  CBA  period  (Fig.  1).  No  factor  was  signif-
cant with  regard  to  infections  or  bacteremia  after
he exclusion  of  colonization  alone.
ase of use
he  response  rate  for  the  questionnaire  on  CBA  use
as 83.3%  (35/42)  (2  senior  physicians,  3  residents,
nd 30  nurses).  All  35  respondents  had  used  the
roduct  for  at  least  2  months,  and  25/35  had  used
t from  the  date  of  the  protocol  switch.  Users  liked
he product’s  bottle,  the  ‘‘no-stains-on-sheets’’
spect,  and  the  need  to  use  only  one  rather  than
everal  products  (Table  4).  However,  the  cleansing
ffect  of  CBA  for  CVC  care  was  considered  to  be
imited  (Likert  score  of  3.3/4).  In  addition,  the  fact
hat it  was  colorless  was  considered  to  be  a  major
t
f
p
trawback  for  both  CVC  insertion  and  care  (Likert
core of  3.3/4  and  3.2/4  in  response  to  ‘‘absence
f color  bothersome’’).
ost
ecause  CBA  cannot  be  used  for  disinfection  of
he mucosa,  a PVP-I  aqueous  formulation  suitable
or the  mucosa  (Betadine  dermique®) was  used
hroughout  the  two  study  periods,  together  with  a
imited number  of  units  of  PVP-I  scrub  and  PVP-IA.
he comparison  of  antiseptic  costs  included  all  of
he products  that  were  consumed  during  7-month
eriods with  similar  bed  occupancy.  The  consump-
ion of  Betadine  aqueous  solution,  which  was  used
or additional  CVC  care,  was  similar  between  the
eriods. Biseptine  consumption  replaced  the  reduc-
ion in  Betadine  scrub  and  Betadine  alcohol-based
40  R.  Girard  et  al.
Table  4  Likert  score  means  on  ease  of  CBA  use  (on  4).
Likert  score  means  (SD) No  response  n  (%)
Bottle  quality
Good  size  3.6  (0.6)  1  (2.9)
Easy  to  pour 3.4  (0.7)  0  (—)
No  spill 3.2 (1.1)  0  (—)
Ease  of  use  for  CVC  insertion
Cleansing  effect  adequate  3.2  (0.7)  8  (22.8)
Absence  of  color  bothersome  3.3  (0.9)  1  (2.9)
Protocol  easy  to  implement  3.6  (0.5)  1  (2.9)
Ease  of  use  for  care  and  dressings
Cleansing  effect  adequate 3.3  (0.7)  11  (31.4)
Absence  of  color  bothersome 3.2  (1.0)  2  (5.7)
Protocol  easy  to  implement  3.6  (0.5)  2  (5.7)
Good  tolerance  3.5  (0.5)  3  (85)
Maceration  under  gauze  1.7  (0.7)  6  (17.1)
Maceration  under  transparent  dressing 2.0  (0.7)  8  (22.8)
Results given as mean ± SD.
Values of Likert score: 1 point if the response is ‘‘totally disagree’’, 2 points if it is ‘‘rather disagree’’, 3 points if it is ‘‘rather
agree’’ and 4 points if it is ‘‘totally agree.
Table  5  Cost  comparison  over  7  months.
PVP-IA  period
(June—December  2007)
CBA  period  (June—December
2008)
Quantity  Cost  (D)a Quantity  Cost  (D)a
Biseptine® (250-ml  bottle)  —  —  920  1684
Betadine  scrub  (125-ml  bottle)  571  405  284  212
Betadine  —  aqueous  solution  (125-ml  bottle)  457  143  488  140
Betadine  —  alcoholic  solution  (125-ml  bottle)  1094  1396  101  133
Total  1943  2168
Monthly  cost  278  310
a Inclusive of value added tax.
Figure  1  CVC  colonization  or  infection-free  survival  (Cox  multivariate  proportional  hazards  model,  p  =  0.04)  (solid
line:  PVP-IA;  dashed  line:  CBA),  adjusted  for  patient  age  and  gender,  SAPS  II,  immunodeﬁciency,  antibiotic  treatment
at  admission,  intubations  (including  duration),  bladder  catheterization  (including  duration),  other  hospital-acquired
infections,  and  CVC  insertion  site.
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[ntiseptic  for  the  prevention  of  central  venous  cath
olution  use  (Table  5).  Costs  after  the  protocol
witch from  PVP-IA  to  CBA  were  slightly  higher.
iscussion
ur  study  found  that  the  period  of  CBA  use  was  asso-
iated with  a  slightly  lower  risk  of  CVC  colonization
nd bacteremia  but  was  also  associated  with  cer-
ain drawbacks.  Many  users  considered  its  cleansing
ctivity  to  be  too  limited  and  were  bothered  by  the
act that  the  solution  was  colorless.  The  cost  was
o lower  than  that  of  PVP-IA  use.
It is  unlikely  that  the  lower  CVC  colonization
isk observed  during  CBA  use  was  due  to  guidance
rovided before  switching  the  protocol  for  several
easons.  During  PVP-IA  use  (ﬁrst  study  period),  the
VC colonization  and  infection  rates  were  already
ower  than  those  reported  by  Lorente  et  al.  [14]
nd Parienti  et  al.  [3]  and  close  to  those  reported  by
alles et  al.  [10]  for  chlorhexidine.  Bacterial  counts
uring this  period  were  similar  to  those  found  by
shizuka  et  al.  [9].  In  addition,  our  ICU  staff,  as
ell as  the  new  arrivals,  beneﬁted  from  a  continu-
us education  program  that  includes  training  in  CVC
nsertion and  care.
In  contrast  to  earlier  studies,  we  found  only  a
light advantage  of  using  CBA  over  PVP-IA.  One
xplanation  may  be  that  we  used  alcohol-based  and
ot aqueous  PVP-I  during  the  ﬁrst  study  period.  Most
f the  studies  that  have  found  CBA  to  be  more  effec-
ive have  compared  it  to  an  aqueous  PVP-I  solution
5,10,11]. Parienti  et  al.  [3]  showed  that  alcohol-
ased  PVP-I  was  better  than  aqueous  PVP-I,  and
imoz et  al.  [15],  the  only  team  to  compare  CBA
o a  PVP-IA,  reported  that  CBA  was  more  effective.
A limitation  of  our  study  as  an  in-depth  product
omparison is  that  it  was  a  ﬁeld  study.  A  randomized
rial is  better  at  addressing  all  of  the  confounding
actors. It  is  also  possible  that  not  all  ICU  staff  com-
lied with  the  protocol  switch  on  the  planned  date.
hese differences  might  explain  why  the  Mimoz
t al.  randomized  trial  recorded  a  signiﬁcant  dif-
erence in  favor  of  CBA.
CBA  users  liked  using  the  same  product  for
leansing and  antisepsis  but  considered  the  fact
hat it  was  colorless  to  be  a  major  drawback
ecause the  quality  of  antisepsis  depends  on  ensur-
ng full  application  [16,17].  It  is  uncertain  whether
 switch  from  PVP-IA  to  CBA  would  be  beneﬁ-
ial until  the  results  are  available  for  colored  CBA
roducts.  A  drawback  of  CBA  is  that  it  cannot  be
sed for  mucosa.  Different  products  need  to  be
tocked  and  managed.  In  conclusion,  the  best  strat-
gy for  CVC  antisepsis  in  an  ICU  is  complex  and  must
[r-related  infections  41
onsider  not  only  microbiological  efﬁcacy  but  also
he ease  of  use  and  organizational  aspects,  espe-
ially because  the  small  differences  observed  in
fﬁcacy have  limited  clinical  signiﬁcance.
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